ライフサイエンスコーパス: PCI

1 PCI of angiographically mild lesions with large plaque b

2 PCI prevents death, cardiac death, and MI in patients wi

3 PCI score >= 30 was associated with worse survival (p =

4 PCI score was correlated with overall survival (p = 0.00

5 PCI was associated with a significantly higher rate and

6 Among 280 PCI subjects in a nested inflammatory biomarker substudy

7 reduction 21%, 95% CI 12-29) and NSTEMI (383 PCI procedures per week in 2019 vs 240 by the end of Mar

8 procedures for patients with both STEMI (438 PCI procedures per week in 2019 vs 346 by the end of Mar

9 Of 74 953 PCIs, 9.4% used no BAS, 12.0% used BIV alone, 20.8% used

10 and symptoms of patients who recently had a PCI.

11 Additionally, PCI in stable patients has not been shown to improve sur

12 After adjustment, PCI of unstable coronary lesions was independently assoc

13 revascularisation was estimated in 17% after PCI versus 10% after CABG (HR 1.73 [95% CI 1.25-2.40]; p

14 cardial infarction was estimated in 8% after PCI versus 3% after CABG (HR 2.99 [95% CI 1.66-5.39]; p=

15 ll-cause mortality was estimated in 9% after PCI versus 9% after CABG (HR 1.08 [95% CI 0.74-1.59]; p=

16 In adults with AF after PCI, dual therapy reduces risk for bleeding compared wit

17 nts had greater odds of developing AKI after PCI compared with White patients.

18 vity C-reactive protein concentrations after PCI when compared with placebo but did not lower the ris

19 However, achieving CR after PCI or CABG surgery might not be feasible owing to patie

20 ence of myocardial ischemia, different after PCI and CABG.

21 Improved cholesterol management after PCI should be considered to improve the outcomes of thes

22 ation of aspirin therapy 1 to 3 months after PCI significantly reduced the risk of major bleeding by

23 scontinuation of aspirin 1 to 3 months after PCI with continued P2Y(12) inhibitor monotherapy compare

24 nts had LDL-C measured within 6 months after PCI, and only 57% had LDL-C <70 mg/dl.

25 of bleeding when stopped 1 to 3 months after PCI.

26 p duration ranged from 12 to 15 months after PCI.

27 11.94; 95% CI: 4.84 to 29.47) but not after PCI (adjusted HR: 1.14; 95% CI: 0.35 to 3.67) (p(interac

28 olesterol (LDL-C) may improve outcomes after PCI, practice guidelines do not have specific recommenda

29 required to improve long-term outcomes after PCI.

30 occurred in 34 of 935 (3.6%) patients after PCI and 56 of 923 (6.1%) patients after CABG (difference

31 The rates of PMI after PCI and CABG vary greatly with different definitions.

32 PMIs after PCI were associated with 10-year mortality regardless of

33 ars tended to be lower after CABG than after PCI, with a similar treatment effect for female and male

34 MACE rates within 1 year after PCI were progressively lower after treatment with BMS ve

35 ithin year 1 and between 1 and 5 years after PCI with bare-metal stents (BMS), first-generation drug-

36 and longer-term cardiovascular events after PCIs.

37 s to evaluate LDL-C testing and levels after PCIs, and to assess the association between LDL-C and lo

38 ISR represents approximately 10% of all PCI and is treated most commonly with another stent. App

39 compared with optimal medical therapy alone, PCI was associated with MACCE reductions only in those w

40 GA and PCI (i.e., BCG) show weaker associations with clinical M

41 GA and PCI also deteriorated significantly each minute during t

42 imilar to other neurological cohorts, GA and PCI may be important parameters to assess and target in

43 ication, periprocedural AKI prophylaxis, and PCI procedural characteristics, Black race was associate

44 The rate of appropriate PCI was high and was associated with the greatest health

45 cclusion PCI, the rate of rarely appropriate PCI was low.

46 s the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timel

47 ion was used to model PCI scores on baseline PCI, treatment, and other factors.

48 ence value ascertained within 30 days before PCI.

49 tensified oral loading strategy (ILS) before PCI impacts on outcomes among these patients in contempo

50 ibitum food during the 4-day-interval before PCI.

51 was no difference in early mortality between PCI and CABG (2.4% vs. 2.3%; p = 0.721) after matching.

52 at 5 years in the SYNTAXES (Synergy between PCI with Taxus and Cardiac Surgery Extended Survival) tr

53 (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Surv

54 (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Surv

55 raction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI, 1.34-2.21]; no

56 azard of cardiovascular mortality after both PCI and CABG (p(interaction) = 0.86).

57 For both PCI and CABG, BPCI participation was not associated with

58 HCR integrates the positive features of both PCI and CABG, albeit requiring 2 procedures rather than

59 For stable CAD, PCI did not reduce mortality (RR, 0.98 [95% CI, 0.87-1.1

60 For patients with stable CAD, PCI shows no evidence of an effect on any of these outco

61 In unstable CAD, PCI also reduced cardiac death (RR, 0.69 [95% CI, 0.53-0

62 FACT-Cog PCI scores were significantly lower, indicating more imp

63 In the ischemic FFR cohort, PCI was associated with a significantly lower rate and h

64 ul for operators who plan to perform complex PCI procedures.

65 patient data pooled analysis of contemporary PCI trials, women had a higher risk of MACE and ID-TLR c

66 CTO-PCI success increased with operator experience (45% and

67 CTO-PCI was defined as intervention of a 100% occluded coron

68 Operator and hospital CTO-PCI experiences were directly related to procedural succ

69 These data suggested that CTO-PCI safety and success could potentially be improved by

70 cess and outcomes of patients undergoing CTO-PCI.

71 ts enrolled in the registry, 7389 (3.5%) CTO-PCIs were attempted with a success rate of 53%.

72 cardiac event among patients undergoing CTO-PCIs.

73 At discharge, PCI of unstable lesions was associated with twice-higher

74 sation of left main coronary artery disease, PCI was associated with an inferior clinical outcome at

75 merican guidelines for the use of FFR during PCI and shows that intracoronary pressure wire guidance

76 on to Treat Multi-vessel Disease After Early PCI for STEMI) trial, angiography-guided percutaneous co

77 or 3-vessel CAD who were treated with either PCI or isolated CABG from 2008 to 2017.

78 aged 21-85 years and had had either elective PCI for stable angina or urgent PCI for unstable angina

79 trial tested the hypothesis that in elective PCI prasugrel 60 mg (ILS) is superior to standard loadin

80 Emergent PCI of unstable lesions is associated with improved surv

81 Emergent PCI was performed in 478 patients (91.4% of unstable and

82 Following PCI with contemporary drug-eluting stents, stent implant

83 AA following PCI were infrequent but were associated with increase in

84 D-TLR compared with men at 5 years following PCI.

85 For PCI, payments increased at both BPCI and control hospita

86 ascular events (C-index=0.65 [0.61-0.69] for PCI and C-index=0.71 [0.67-0.75] for CABG).

87 discrimination (C-index=0.67 [0.63-0.70] for PCI and C-index=0.62 [0.58-0.66] for CABG) and good cali

88 deaths (C-index=0.73 [95% CI 0.69-0.76] for PCI and 0.73 [0.69-0.76] for CABG) and 5-year major adve

89 tient files to identify index admissions for PCI and CABG from 2013 through 2016 at BPCI hospitals an

90 Forty-two hospitals joined BPCI for PCI and 46 for CABG.

91 Baseline Medicare payments per episode for PCI were $20 164 at BPCI hospitals and $19 955 at contro

92 vention (PCI) irrespective of indication for PCI may fail to account for the substantial risk of subs

93 lly nonobstructive stenosis not intended for PCI but with IVUS plaque burden of >=65% were randomized

94 Participation in episode-based payment for PCI and CABG was not associated with changes in patient

95 known whether established FFR thresholds for PCI are adhered to in routine interventional practice an

96 nstable) influences the benefit derived from PCI.

97 Average time from PCI to randomization was 5.4 years (SD, 4.4) and follow-

98 ed with fractional flow reserve (FFR)-guided PCI compared with CABG.

99 larization was more frequent with FFR-guided PCI (24.9% versus 8.2%; hazard ratio, 3.51 [95% CI, 1.93

100 vascular events was higher in the FFR-guided PCI versus the CABG group (44.5% versus 31.9%; hazard ra

101 ebrovascular events compared with FFR-guided PCI, driven by a higher rate of repeat revascularization

102 9 patients underwent CABG and 209 FFR-guided PCI.

103 ction, or stroke between CABG and FFR-guided PCI.

104 Physiology-guided PCI has shown to improve clinical outcomes in multivesse

105 n this contemporary cohort, patients who had PCI to their LRPV had a higher-risk profile and more adv

106 the 20-item Perceived Cognitive Impairment (PCI) scale, our primary end point.

107 and has resulted in a significant decline in PCI procedures.

108 The decrease was greatest in PCI procedures performed for stable angina (66%), follow

109 y, few resources exist to train operators in PCI complication management.

110 ry of diabetes, prior myocardial infarction, PCI, and coronary artery bypass grafting.

111 ion with percutaneous coronary intervention (PCI) and antianginal therapy.

112 omes for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) is unkno

113 ollowing percutaneous coronary intervention (PCI) and coronary bypass grafting (CABG) surgery exist.

114 n during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adve

115 E) after percutaneous coronary intervention (PCI) are believed to occur within the first year.

116 dergoing percutaneous coronary intervention (PCI) for ISR in the United States.

117 ther the percutaneous coronary intervention (PCI) group or coronary artery bypass grafting (CABG) gro

118 ollowing percutaneous coronary intervention (PCI) have reported conflicting results.

119 ollowing percutaneous coronary intervention (PCI) irrespective of indication for PCI may fail to acco

120 dergoing percutaneous coronary intervention (PCI) is a risk factor for AKI development, but few studi

121 Percutaneous coronary intervention (PCI) is increasingly used in revascularisation of patien

122 F) after percutaneous coronary intervention (PCI) is unclear.

123 cclusion percutaneous coronary intervention (PCI) is unknown.

124 story of percutaneous coronary intervention (PCI) is unknown.

125 tions of percutaneous coronary intervention (PCI) may have significant impact on patient survival and

126 died for percutaneous coronary intervention (PCI) of chronic total occlusion (CTO).

127 comes of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques.

128 y-guided percutaneous coronary intervention (PCI) of nonculprit lesions with the aim of complete reva

129 ne after percutaneous coronary intervention (PCI) or acute coronary syndrome but with increased risk

130 ion with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery.

131 anges in percutaneous coronary intervention (PCI) practice in England by analyzing procedural numbers

132 ditional percutaneous coronary intervention (PCI) procedures performed at a tertiary care center in t

133 arction, percutaneous coronary intervention (PCI) reduces mortality when compared with fibrinolysis.

134 dergoing percutaneous coronary intervention (PCI) treated with MCS (Impella or intra-aortic balloon p

135 elective percutaneous coronary intervention (PCI), periprocedural thrombotic and bleeding complicatio

136 ither by percutaneous coronary intervention (PCI), with low risk of immediate complications, or coron

137 mitigate percutaneous coronary intervention (PCI)-related bleeding.

138 e during percutaneous coronary intervention (PCI).

139 possible percutaneous coronary intervention (PCI).

140 ions for percutaneous coronary intervention (PCI).

141 its over percutaneous coronary intervention (PCI).

142 eated by percutaneous coronary intervention (PCI).

143 dergoing percutaneous coronary intervention (PCI).

144 dergoing percutaneous coronary intervention (PCI).

145 ocedure (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or optim

146 llowing percutaneous coronary interventions (PCI) is not well studied.

147 After percutaneous coronary interventions (PCIs), patients remain at high risk of developing late c

148 rences between patients with ISR and non-ISR PCI for in-hospital complications and hospital length of

149 are comparable with those undergoing non-ISR PCI.

150 In-hospital outcomes of patients with ISR PCI are comparable with those undergoing non-ISR PCI.

151 e consistent irrespective of time since last PCI.

152 versus 25.6%, P=0.013), while stable lesions PCI did not improve survival (25.5% versus 26.3%, P=1.00

153 We analyzed a large longitudinal PCI cohort (2007-2014, n=501 841) from the British Cardi

154 gnificantly better BCG as reflected by lower PCI values in comparison to the other two MS severity gr

155 CI, 1.42-2.19], P<0.001) were higher in LRPV PCI group as compared to control group.

156 Mortality was higher in the LRPV PCI group during hospital admission (12 % versus 1.5 %,

157 Patients in the LRPV PCI group were older, had more comorbidities, and higher

158 irin produced consistent reductions in MACE (PCI: 4.0% versus 5.5%; hazard ratio [HR], 0.74 [95% CI,

159 us, comorbidities, predisposing medications, PCI indication, periprocedural AKI prophylaxis, and PCI

160 iori and linear regression was used to model PCI scores on baseline PCI, treatment, and other factors

161 61-0.94], P-interaction=0.85) and mortality (PCI: 2.5% versus 3.5%; HR, 0.73 [95% CI, 0.58-0.92]; no

162 ous myocardial infarction 74.8%, multivessel PCI 38.0%).

163 ss of HCR compared with CABG and multivessel PCI alone.

164 amine whether HCR is superior to multivessel PCI.

165 (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) demonstrated superior outcome

166 e Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock), patients with CS complicating

167 Cardiovascular Intervention Society national PCI database were analyzed for all uLMS-PCI procedures p

168 ersus 2.0%; HR, 1.72 [95% CI, 1.34-2.21]; no PCI: 2.9% versus 1.8%; HR, 1.58 [95% CI, 1.15-2.17], P-i

169 ard ratio [HR], 0.74 [95% CI, 0.61-0.88]; no PCI: 4.4% versus 5.7%; HR, 0.76 [95% CI, 0.61-0.94], P-i

170 ersus 3.5%; HR, 0.73 [95% CI, 0.58-0.92]; no PCI: 4.1% versus 5.0%; HR, 0.80 [95% CI, 0.64-1.00], P-i

171 r ACS according to index strategy (PCI or no PCI) and to contrast with the association between post-d

172 d hazard of MACE at 5 years compared with no PCI (31.5% vs 39.1%; hazard ratio, 0.77 [95% CI, 0.63-0.

173 d hazard of MACE at 5 years compared with no PCI (33.3% vs 24.4%; HR, 1.37 [95% CI, 1.14-1.65]) in th

174 sis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations

175 patients undergoing chronic total occlusion PCI, the rate of rarely appropriate PCI was low.

176 th status data after chronic total occlusion PCI.

177 is meta-analysis, we examine the benefits of PCI in (1) patients post-myocardial infarction (MI) who

178 effective treatment, and team-based care of PCI complications.

179 eived a device before or after initiation of PCI.

180 The magnitude of PCI change scores was greater for CT+E than E at 3 month

181 s, 52% had LDL-C measured within 6 months of PCI and 57% had LDL-C <70 mg/dl.

182 2020), there was a 49% fall in the number of PCI procedures after the 12th week in 2020.

183 l, reductions were recorded in the number of PCI procedures for patients with both STEMI (438 PCI pro

184 ts who underwent PCI, the primary outcome of PCI-related myocardial injury did not differ between col

185 udy compared early and long-term outcomes of PCI versus CABG in patients with diabetes.

186 These findings support the performance of PCI procedures according to evidence-based FFR threshold

187 Predictors of PCI included increasing age, male gender, and personal h

188 0.85 [0.76-0.96], P=0.01) and lower rates of PCI failure or complication requiring coronary artery by

189 d with placebo but did not lower the risk of PCI-related myocardial injury.

190 performed a retrospective cohort analysis of PCIs from 18 facilities within one health care system fr

191 The CULPRIT-SHOCK trial (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) demonst

192 CULPRIT-SHOCK trial (The Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock), patien

193 viduals who will benefit from either CABG or PCI, thereby supporting heart teams, patients, and their

194 2 groups; LRPV group (n=2432) and all other PCI groups (n=506 691).

195 The estimated treatment benefit of CABG over PCI varied substantially among patients in the trial pop

196 Among hospitals performing PCI (n=1672), 577 (34.5%) did not perform any CA.

197 performing PCI, compared with not performing PCI, was significantly associated with a lower rate of M

198 ent in routine clinical practice, performing PCI, compared with not performing PCI, was significantly

199 e-site trial, subjects referred for possible PCI (n=714) were randomized to acute preprocedural oral

200 Deltacreatinine post PCI in the DR group vs. the control group did not show a

201 5-fold relative elevation within 7 days post-PCI from the reference value ascertained within 30 days

202 ns did not differ between groups 1-hour post-PCI but increased less 24 hours post-PCI in the colchici

203 ur post-PCI but increased less 24 hours post-PCI in the colchicine (n=141) versus placebo group (n=13

204 ) are associated with increased risk of post-PCI adverse outcomes.

205 tion (23.5% versus 26.7%, P=0.008), previous PCI (24.3% versus 28.3%, P=0.001), or previous coronary

206 coronary syndrome with or without a previous PCI treated with DPI versus aspirin alone.

207 Among patients with a previous PCI, we studied the effects of treatment according to th

208 in, and, of these, 9862 (59.6%) had previous PCI (mean age 68.2+/-7.8, female 19.4%, diabetes mellitu

209 Regardless of previous PCI, DPI versus aspirin produced consistent reductions i

210 in MACE irrespective of time since previous PCI (as early as 1 year and as far as 10 years; P-intera

211 ment according to the timing of the previous PCI.

212 Among those with previous PCI 1 year and beyond, the effects on MACE and mortality

213 In those with previous PCI, DPI compared with aspirin produced consistent (robu

214 Low-Dose Adjunctive Alteplase During Primary PCI [T-TIME]; NCT02257294).

215 Low-Dose Adjunctive Alteplase During Primary PCI), 440 patients with acute ST-segment-elevation myoca

216 During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at P

217 ion; (2) patients who have undergone primary PCI for ST-segment-elevation myocardial infarction but h

218 tals or in specific situations where primary PCI cannot be executed or is not deemed the best option.

219 R-PCI is associated with a significant decrease in radiati

220 que was used (caliper, 0.05) to match each R-PCI patient to the nearest traditional PCI patient witho

221 obotic percutaneous coronary intervention (R-PCI) has been shown to benefit the operator but has not

222 We sought to compare a large cohort of R-PCI to traditional percutaneous coronary intervention (P

223 (minutes) was significantly higher in the R-PCI group (27 [21-40] versus 37 [27-50]; P<0.0005).

224 ; P=0.003) were significantly lower in the R-PCI group.

225 The median radiographic PCI was 25.

226 olled and randomly assigned (1:1) to receive PCI or CABG.

227 atients with an ischemic FFR, 75.3% received PCI and 24.7% were treated only with medical therapy.

228 myocardial infarction) in patients receiving PCI or CABG.

229 Forty-four hospitals reported PCI procedures for 126 491 patients.

230 nt CATH (69%), of whom 10% had CAD requiring PCI.

231 nce in chronic total occlusion and high-risk PCI.

232 Overall, in these unstable scenarios PCI was associated with a significant reduction in morta

233 In the 3 unstable scenarios, PCI had the following effects on mortality: unrevascular

234 The postcolumn infused internal standard (PCI-IS) method was applied to estimate spot volume and q

235 ality after ACS according to index strategy (PCI or no PCI) and to contrast with the association betw

236 pectroscopy (NIRS) catheter after successful PCI of all flow-limiting coronary lesions in 898 patient

237 ng optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the

238 ment in patients who had a recent successful PCI.

239 apy in patients who had undergone successful PCI at 365 centres in 27 countries across Europe, South

240 The result showed that PCI-IS was an accurate and efficient LC-MS/MS method to

241 [(13)C(6)]-Rivaroxaban was selected as the PCI-IS.

242 SCAI or EXCEL definition were higher in the PCI (5.7%) and CABG (16.5%) arms.

243 1201 patients were enrolled and allocated to PCI (n=598) or CABG (n=603), with 17 subsequently lost t

244 9 [95% CI, 1.42-3.09], P<0.001), contrary to PCI of stable lesions (odds ratio, 0.92 [95% CI.

245 val after sudden cardiac arrest, contrary to PCI of stable lesions.

246 CABG was found to be superior to PCI for the primary composite endpoint (p=0.0002).

247 CA represented 1.7% (n=65 033) of the total PCI volume.

248 ach R-PCI patient to the nearest traditional PCI patient without replacement.

249 procedure duration compared with traditional PCI.

250 For transfemoral PCI, VCD+BIV had lower odds of bleeding compared with no

251 in a second stage, with assigned treatment (PCI or CABG) and two prespecified effect-modifiers, whic

252 Operator volume ranged from 1 to 54 uLMS-PCI procedures/year.

253 In total, 6724 uLMS-PCI procedures were analyzed with a negatively skewed di

254 ant factor in determining outcome after uLMS-PCI.

255 onal PCI database were analyzed for all uLMS-PCI procedures performed in England and Wales between 20

256 and 2014 and 4 quartiles of annualized uLMS-PCI volume (Q1-Q4) generated.

257 tem percutaneous coronary intervention (uLMS-PCI) is poorly defined.

258 Higher volume operators undertook uLMS-PCI in patients with greater comorbid burden and perform

259 ty in patients with stable angina undergoing PCI.

260 erentially increased for patients undergoing PCI and decreased for patients undergoing CABG.

261 In patients undergoing PCI for ACS, spontaneous events predominate after 30 day

262 Among patients undergoing PCI for AMI complicated by cardiogenic shock from 2015 t

263 Among 28 304 patients undergoing PCI for AMI complicated by cardiogenic shock, the mean (

264 y, ST, and restenosis in patients undergoing PCI for stable angina pectoris.

265 All patients undergoing PCI in the National Cardiovascular Data Registry CathPCI

266 We identified all patients undergoing PCI in the Veterans Affairs health care system between O

267 trial, which randomized patients undergoing PCI to ticagrelor plus placebo versus ticagrelor plus AS

268 Among patients undergoing PCI treated with MCS, 4782 (9.9%) received Impella; its

269 rapidly increasing among patients undergoing PCI treated with MCS, with marked variability in its use

270 d anatomic complexity of patients undergoing PCI with and without cardiothoracic surgery on-site.

271 plus ASA among high-risk patients undergoing PCI with drug-eluting stents.

272 base, we analyzed 48 306 patients undergoing PCI with MCS at 432 hospitals between January 2004 and D

273 Among the 5,100,394 patients undergoing PCI, 10.6% of patients underwent PCI for ISR lesions.

274 Of the total patients undergoing PCI, we identified those undergoing PCI for ISR lesions.

275 propriate role of MCS in patients undergoing PCI.

276 complicated by cardiogenic shock undergoing PCI between October 1, 2015, and December 31, 2017, who

277 dergoing PCI, we identified those undergoing PCI for ISR lesions.

278 total of 4,519 and 9,716 patients underwent PCI and CABG, respectively.

279 undergoing PCI, 10.6% of patients underwent PCI for ISR lesions.

280 In total, 23,860 patients underwent PCI for stable angina pectoris; of these, FFR guidance w

281 Fewer patients underwent PCI for stable angina.

282 h AKI incidence among patients who underwent PCI at Duke University Medical Center between January 1,

283 were consistent among patients who underwent PCI for an acute coronary syndrome, in whom discontinuat

284 e cohort study of all patients who underwent PCI in England between January 2017 and April 2020 in th

285 Among the 400 subjects who underwent PCI, the primary outcome of PCI-related myocardial injur

286 We identified 75 564 patients who underwent PCI, with the majority (53 708, 71%) treated at sites wi

287 her elective PCI for stable angina or urgent PCI for unstable angina or non-ST segment elevation myoc

288 ng to whether they had an elective or urgent PCI.

289 ate the collective experience of high-volume PCI operators with extensive experience in chronic total

290 , however, it has been controversial whether PCI reduces mortality.

291 The NOBLE trial aimed to evaluate whether PCI was non-inferior to CABG in the treatment of left ma

292 iated with worse survival (p = 0.002), while PCI <= 19 was associated with improved overall survival

293 Compared with PCI, HCR offers the durability and survival advantages o

294 tality and freedom from MACCEs compared with PCI.

295 ificantly lower MACCE rates as compared with PCI.

296 1.86 to 2.12) were significantly higher with PCI compared with CABG.

297 optimal medical therapy alone, patients with PCI experienced a MACCE reduction only if 1-year LDL-C w

298 the two procedures but patients treated with PCI had higher rates of non-procedural myocardial infarc

299 artery disease randomized to treatment with PCI or CABG in the SYNTAX trial.

300 e interaction between sex and treatment with PCI or CABG that was observed at 5 years was no longer p

301 lity in participants treated with or without PCI and has an equivalent prognostic impact as post-disc

302 tent in participants treated with or without PCI for their index ACS (p for interaction = 0.240).